Close Menu

cytogenetics

What will regulatory clearance mean for companies that manufacture chromosomal microarrays?

This article was originally posted on Feb. 1

By the end of next year, all of the large array vendors could have US Food and Drug Administration-cleared products on the market for postnatal constitutional cytogenetics.

Illumina's acquisition of BlueGnome has provided a boost for its array business.

SAN FRANCISCO — Illumina will not be the only array vendor submitting a cytogenetics-focused array to the US Food and Drug Administration for clearance this quarter.

Illumina CEO Jay Flatley provided an update on the company's array business at the JP Morgan Global Healthcare Conference in San Francisco this week.

Things are looking up for CombiMatrix. The Irvine, Calif.-based molecular diagnostics firm this week reported preliminary revenue growth of 172 percent and 171 percent for billable prenatal tests in the fourth quarter of 2012 and full year 2012, respectively.

The global adoption of microarrays for the detection of genetic abnormalities has continued into the new year, with Chinese life sciences company CapitalBio announcing recently the introduction of chromosomal microarray analysis services via its medical testing laboratories.

This article was originally posted on Dec. 6.
Several studies published last week in the New England Journal of Medicine underscore the rapidly shifting landscape for genomic tools in the diagnostic setting.

"Explosive" and "enormous" are the words Simon Sheng uses to describe the market for microarray technology in China. As general manager for Affymetrix's office in the country, Sheng said he has hired eight sales and marketing personnel this year and hopes to add more soon.

Pages

Researchers have sequenced the genome of the depth-dwelling giant squid.

Prosecutors have charged a former Drexel University professor with theft for allegedly spending federal grant money on adult entertainment and other unrelated expenses, according to the Philadelphia Inquirer.

 

Chris Collins, a former US representative, has been sentenced to more than two years in prison in an insider trading case involving an Australian biotechnology firm, the New York Times reports.

In PNAS this week: Trypanosoma brucei transcripts, estimate of people at risk of inherited retinal disease, and more.